We are testing the safety and effectiveness of crizotinib, alone and with temsirolimus, for children with ALK, ROS1, or MET positive cancers. This study aims to find the best dose and understand how well these treatments work.
Health conditions and diseases that the clinical trial is designed to study and treat.
Neuroblastoma is a rare type of cancer that develops from immature nerve cells, most commonly found in children. It can occur in various parts of the body, often in the adrenal glands, and may cause symptoms like abdominal pain, a lump, or changes in bowel habits.
Anaplastic Large Cell Lymphoma (ALCL) is a rare type of non-Hodgkin lymphoma that can affect lymph nodes and other organs. Symptoms may include swollen lymph nodes, fever, and weight loss.
Inflammatory Myofibroblastic Tumors (IMT) are rare tumors that can occur in various tissues, often causing swelling and pain. They are characterized by the presence of myofibroblasts and can be mistaken for other types of tumors.
ALK/ROS1/MET-positive malignancies are rare cancers characterized by specific genetic mutations that can affect treatment options. Symptoms vary depending on the type and location of the cancer.
Rhabdomyosarcoma (RMS) is a rare type of soft tissue sarcoma that primarily affects children and adolescents. It can occur in various locations, including the head, neck, and limbs, causing symptoms like swelling and pain.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
